Literature DB >> 20696170

Gene therapy strategies for cardiac electrical dysfunction.

Ian Greener1, J Kevin Donahue.   

Abstract

Cardiac disease is frequently associated with abnormalities in electrical function that can severely impair cardiac performance with potentially fatal consequences. The available therapeutic options have some efficacy but are far from perfect. The curative potential of gene therapy makes it an attractive approach for the treatment of cardiac arrhythmias. To date, gene therapy research strategies have targeted three major classes of cardiac arrhythmias: (1) ventricular arrhythmias, (2) atrial fibrillation, and (3) bradyarrhythmias. Various vehicles for gene transfer have been employed with adeno-associated viral gene delivery being the preferred choice for long-term gene expression and adenoviral gene delivery for short-term proof-of-concept work. In combination with the development of novel delivery methods, gene therapy may prove to be an effective strategy to eliminate the most debilitating of arrhythmias. This article is part of a Special Section entitled "Special Section: Cardiovascular Gene Therapy".
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20696170      PMCID: PMC3032832          DOI: 10.1016/j.yjmcc.2010.07.022

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  42 in total

Review 1.  Latest development in viral vectors for gene therapy.

Authors:  Kenneth Lundstrom
Journal:  Trends Biotechnol       Date:  2003-03       Impact factor: 19.536

2.  Biological pacemaker created by gene transfer.

Authors:  Junichiro Miake; Eduardo Marbán; H Bradley Nuss
Journal:  Nature       Date:  2002-09-12       Impact factor: 49.962

3.  Systemic delivery of genes to striated muscles using adeno-associated viral vectors.

Authors:  Paul Gregorevic; Michael J Blankinship; James M Allen; Robert W Crawford; Leonard Meuse; Daniel G Miller; David W Russell; Jeffrey S Chamberlain
Journal:  Nat Med       Date:  2004-07-25       Impact factor: 53.440

4.  Focal modification of electrical conduction in the heart by viral gene transfer.

Authors:  J K Donahue; A W Heldman; H Fraser; A D McDonald; J M Miller; J J Rade; T Eschenhagen; E Marbán
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

5.  Expression and function of a biological pacemaker in canine heart.

Authors:  Jihong Qu; Alexei N Plotnikov; Peter Danilo; Iryna Shlapakova; Ira S Cohen; Richard B Robinson; Michael R Rosen
Journal:  Circulation       Date:  2003-03-04       Impact factor: 29.690

6.  Long-term restitution of 4-aminopyridine-sensitive currents in Kv1DN ventricular myocytes using adeno-associated virus-mediated delivery of Kv1.5.

Authors:  S A Kodirov; M Brunner; L Busconi; G Koren
Journal:  FEBS Lett       Date:  2003-08-28       Impact factor: 4.124

7.  Biological pacemaker implanted in canine left bundle branch provides ventricular escape rhythms that have physiologically acceptable rates.

Authors:  Alexei N Plotnikov; Eugene A Sosunov; Jihong Qu; Iryna N Shlapakova; Evgeny P Anyukhovsky; Lili Liu; Michiel J Janse; Peter R Brink; Ira S Cohen; Richard B Robinson; Peter Danilo; Michael R Rosen
Journal:  Circulation       Date:  2004-01-20       Impact factor: 29.690

8.  The incorporation of an ion channel gene mutation associated with the long QT syndrome (Q9E-hMiRP1) in a plasmid vector for site-specific arrhythmia gene therapy: in vitro and in vivo feasibility studies.

Authors:  Denise Y Burton; Cunxian Song; Ilia Fishbein; Senator Hazelwood; Quanyi Li; Suzanne DeFelice; Jeanne M Connolly; Itay Perlstein; Douglas A Coulter; Robert J Levy
Journal:  Hum Gene Ther       Date:  2003-06-10       Impact factor: 5.695

9.  In vivo gene transfer of Kv1.5 normalizes action potential duration and shortens QT interval in mice with long QT phenotype.

Authors:  Michael Brunner; Sodikdjon A Kodirov; Gary F Mitchell; Peter D Buckett; Katsushi Shibata; Eduardo J Folco; Linda Baker; Guy Salama; Danny P Chan; Jun Zhou; Gideon Koren
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-07       Impact factor: 4.733

10.  'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo.

Authors:  D Bonci; A Cittadini; M V G Latronico; U Borello; J K Aycock; A Drusco; A Innocenzi; A Follenzi; M Lavitrano; M G Monti; J Ross; L Naldini; C Peschle; G Cossu; G Condorelli
Journal:  Gene Ther       Date:  2003-04       Impact factor: 5.250

View more
  10 in total

Review 1.  Regenerative therapies in electrophysiology and pacing: introducing the next steps.

Authors:  Gerard J J Boink; Michael R Rosen
Journal:  J Interv Card Electrophysiol       Date:  2010-12-16       Impact factor: 1.900

Review 2.  Gene therapies for arrhythmias in heart failure.

Authors:  Fadi G Akar; Roger J Hajjar
Journal:  Pflugers Arch       Date:  2014-02-26       Impact factor: 3.657

Review 3.  Gene therapy to restore electrophysiological function in heart failure.

Authors:  Lukas J Motloch; Fadi G Akar
Journal:  Expert Opin Biol Ther       Date:  2015-04-12       Impact factor: 4.388

Review 4.  Gene therapy for atrial fibrillation - How close to clinical implementation?

Authors:  Amar Trivedi; Jacob Hoffman; Rishi Arora
Journal:  Int J Cardiol       Date:  2019-08-07       Impact factor: 4.164

Review 5.  Cardiovascular gene therapy for myocardial infarction.

Authors:  Maria C Scimia; Anna M Gumpert; Walter J Koch
Journal:  Expert Opin Biol Ther       Date:  2013-12-16       Impact factor: 4.388

6.  The Use of Gene Therapy for Ablation of Atrial Fibrillation.

Authors:  Zhao Liu; J Kevin Donahue
Journal:  Arrhythm Electrophysiol Rev       Date:  2014-11-29

Review 7.  Recent advances in gene therapy for atrial fibrillation.

Authors:  Shin Yoo; Gail Elizabeth Geist; Anna Pfenniger; Markus Rottmann; Rishi Arora
Journal:  J Cardiovasc Electrophysiol       Date:  2021-07-06       Impact factor: 2.942

Review 8.  Gene Therapy for the Treatment of Cardiac Arrhythmias: Current and Emerging Applications.

Authors:  Amar Trivedi; Rishi Arora
Journal:  J Innov Card Rhythm Manag       Date:  2018-12-15

Review 9.  Modified mRNA as a Therapeutic Tool for the Heart.

Authors:  Keerat Kaur; Lior Zangi
Journal:  Cardiovasc Drugs Ther       Date:  2020-08-21       Impact factor: 3.727

10.  Genetically engineered excitable cardiac myofibroblasts coupled to cardiomyocytes rescue normal propagation and reduce arrhythmia complexity in heterocellular monolayers.

Authors:  Luqia Hou; Bin Hu; José Jalife
Journal:  PLoS One       Date:  2013-02-05       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.